Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
285 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT02470091 | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 56 | Children's Oncology GroupNETWORK | 3 | Jan 22, 2024 | clinicaltrials |
| NCT05820191 |
| B-amyloid as a Marker for GBM Bioimaging |
| unknown |
| Phase 2 |
| 3 |
| Universidad Central del CaribeOTHER |
| 1 |
| Dec 21, 2023 |
| clinicaltrials |
| NCT03414983 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread(CheckMate 9X8) | completed | Phase 2 / Phase 3 | 196 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 18, 2023 | clinicaltrials |
| NCT02484443 | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 5 | Oct 26, 2023 | clinicaltrials |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | completed | Phase 1 / Phase 2 | 113 | Ionis Pharmaceuticals, Inc.INDUSTRY | 6 | Oct 6, 2023 | clinicaltrials |
| NCT05243524 | Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer(AVALON) | terminated | Phase 2 | 16 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 3 | Sep 13, 2023 | clinicaltrials |
| NCT00003692 | Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 128 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 18, 2023 | clinicaltrials |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 / Phase 2 | 40 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 20, 2023 | clinicaltrials |
| NCT02226965 | PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) | completed | Phase 2 | 45 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 29, 2023 | clinicaltrials |
| NCT00003237 | Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach | completed | Phase 2 | 55 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00003308 | Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT00003808 | Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00005962 | Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00004223 | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT00003864 | Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 15, 2023 | clinicaltrials |
| NCT00004860 | Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT00006004 | Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 15, 2023 | clinicaltrials |
| NCT00041314 | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 15, 2023 | clinicaltrials |
| NCT04648020 | Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.(VOICE) | terminated | Phase 2 / Phase 3 | 190 | Monopar TherapeuticsINDUSTRY | 5 | May 31, 2023 | clinicaltrials |
| NCT02017964 | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma | completed | Phase 2 | 26 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2023 | clinicaltrials |
| NCT01767194 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 5 | Oct 24, 2022 | clinicaltrials |
| NCT04075604 | A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer(CheckMate 7A8) | completed | Phase 2 | 23 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 10, 2022 | clinicaltrials |
| NCT02961374 | Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2022 | clinicaltrials |
| NCT03951077 | Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome | completed | Phase 2 | 118 | AbbVieINDUSTRY | 2 | Jun 8, 2022 | clinicaltrials |
| NCT02487979 | Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 3 | Jan 18, 2022 | clinicaltrials |
| NCT01460160 | Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia | completed | Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 6 | Dec 8, 2021 | clinicaltrials |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | terminated | Phase 2 | 13 | BeiGeneINDUSTRY | 4 | Nov 17, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT00001114 | The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma | completed | Phase 2 | 90 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 2 | Nov 1, 2021 | clinicaltrials |
| NCT01008150 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | completed | Phase 2 | 141 | NSABP Foundation IncNETWORK | 5 | Oct 25, 2021 | clinicaltrials |
| NCT02508389 | A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer | completed | Phase 2 | 223 | Galera Therapeutics, Inc.INDUSTRY | 3 | Sep 20, 2021 | clinicaltrials |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 5 | Jul 23, 2021 | clinicaltrials |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT01209325 | Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males | completed | Phase 2 | 149 | AIDS Malignancy ConsortiumNETWORK | 2 | Aug 11, 2020 | clinicaltrials |
| NCT00612586 | Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer | completed | Phase 2 | 117 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 21, 2020 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT00281528 | Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer | terminated | Phase 2 | 208 | CelgeneINDUSTRY | 2 | Nov 22, 2019 | clinicaltrials |
| NCT01490632 | A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis | completed | Phase 2 | 271 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 27, 2019 | clinicaltrials |
| NCT00238264 | Radiation Therapy in Treating Young Patients With Gliomas | completed | Phase 2 | 92 | Children's Oncology GroupNETWORK | 6 | Aug 7, 2019 | clinicaltrials |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | terminated | Phase 2 | 24 | Seagen Inc.INDUSTRY | 2 | Mar 11, 2019 | clinicaltrials |
| NCT00061893 | Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors | completed | Phase 2 | 38 | Children's Oncology GroupNETWORK | 4 | Feb 15, 2019 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT00454779 | PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response | completed | Phase 2 | 113 | AmgenINDUSTRY | 9 | Oct 17, 2018 | clinicaltrials |
| NCT01304524 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3(HPV-003) | completed | Phase 2 | 167 | Inovio PharmaceuticalsINDUSTRY | 9 | Sep 7, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials